These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 25252692)

  • 1. Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma.
    Burd CE; Liu W; Huynh MV; Waqas MA; Gillahan JE; Clark KS; Fu K; Martin BL; Jeck WR; Souroullas GP; Darr DB; Zedek DC; Miley MJ; Baguley BC; Campbell SL; Sharpless NE
    Cancer Discov; 2014 Dec; 4(12):1418-29. PubMed ID: 25252692
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma.
    Sensi M; Nicolini G; Petti C; Bersani I; Lozupone F; Molla A; Vegetti C; Nonaka D; Mortarini R; Parmiani G; Fais S; Anichini A
    Oncogene; 2006 Jun; 25(24):3357-64. PubMed ID: 16462768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coexpression of NRASQ61R and BRAFV600E in human melanoma cells activates senescence and increases susceptibility to cell-mediated cytotoxicity.
    Petti C; Molla A; Vegetti C; Ferrone S; Anichini A; Sensi M
    Cancer Res; 2006 Jul; 66(13):6503-11. PubMed ID: 16818621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.
    Cesi G; Walbrecq G; Zimmer A; Kreis S; Haan C
    Mol Cancer; 2017 Jun; 16(1):102. PubMed ID: 28595656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dual NRASQ61R and BRAFV600E mutation-specific immunohistochemistry completes molecular screening in melanoma samples in a routine practice.
    Uguen A; Guéguen P; Legoupil D; Bouvier S; Costa S; Duigou S; Lemasson G; Ledé F; Sassolas B; Talagas M; Férec C; Le Maréchal C; De Braekeleer M; Marcorelles P
    Hum Pathol; 2015 Nov; 46(11):1582-91. PubMed ID: 26297254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ral activation promotes melanomagenesis.
    Zipfel PA; Brady DC; Kashatus DF; Ancrile BD; Tyler DS; Counter CM
    Oncogene; 2010 Aug; 29(34):4859-64. PubMed ID: 20562921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K; Sun C; Horii A
    Oncol Rep; 2005 Dec; 14(6):1481-5. PubMed ID: 16273242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition.
    Kim HS; Jung M; Kang HN; Kim H; Park CW; Kim SM; Shin SJ; Kim SH; Kim SG; Kim EK; Yun MR; Zheng Z; Chung KY; Greenbowe J; Ali SM; Kim TM; Cho BC
    Oncogene; 2017 Jun; 36(23):3334-3345. PubMed ID: 28092667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. C-MYC overexpression is required for continuous suppression of oncogene-induced senescence in melanoma cells.
    Zhuang D; Mannava S; Grachtchouk V; Tang WH; Patil S; Wawrzyniak JA; Berman AE; Giordano TJ; Prochownik EV; Soengas MS; Nikiforov MA
    Oncogene; 2008 Nov; 27(52):6623-34. PubMed ID: 18679422
    [TBL] [Abstract][Full Text] [Related]  

  • 10. STK11 Prevents Invasion through Signal Transducer and Activator of Transcription 3/5 and FAK Repression in Cutaneous Melanoma.
    Dzung A; Saltari A; Tiso N; Lyck R; Dummer R; Levesque MP
    J Invest Dermatol; 2022 Apr; 142(4):1171-1182.e10. PubMed ID: 34757069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression.
    Omholt K; Platz A; Kanter L; Ringborg U; Hansson J
    Clin Cancer Res; 2003 Dec; 9(17):6483-8. PubMed ID: 14695152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
    Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
    Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.
    Fedorenko IV; Fang B; Munko AC; Gibney GT; Koomen JM; Smalley KS
    Proteomics; 2015 Jan; 15(2-3):327-39. PubMed ID: 25339196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological Targeting of STK19 Inhibits Oncogenic NRAS-Driven Melanomagenesis.
    Yin C; Zhu B; Zhang T; Liu T; Chen S; Liu Y; Li X; Miao X; Li S; Mi X; Zhang J; Li L; Wei G; Xu ZX; Gao X; Huang C; Wei Z; Goding CR; Wang P; Deng X; Cui R
    Cell; 2019 Feb; 176(5):1113-1127.e16. PubMed ID: 30712867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting mitogen-activated protein kinase/extracellular signal-regulated kinase kinase in the mutant (V600E) B-Raf signaling cascade effectively inhibits melanoma lung metastases.
    Sharma A; Tran MA; Liang S; Sharma AK; Amin S; Smith CD; Dong C; Robertson GP
    Cancer Res; 2006 Aug; 66(16):8200-9. PubMed ID: 16912199
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phospho-ERK staining is a poor indicator of the mutational status of BRAF and NRAS in human melanoma.
    Houben R; Vetter-Kauczok CS; Ortmann S; Rapp UR; Broecker EB; Becker JC
    J Invest Dermatol; 2008 Aug; 128(8):2003-12. PubMed ID: 18323787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
    Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
    Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells.
    Eskandarpour M; Kiaii S; Zhu C; Castro J; Sakko AJ; Hansson J
    Int J Cancer; 2005 May; 115(1):65-73. PubMed ID: 15688405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MEK Inhibition Reverses Aberrant Signaling in Melanoma Cells through Reorganization of NRas and BRAF in Self Nanoclusters.
    Yakovian O; Sajman J; Arafeh R; Neve-Oz Y; Alon M; Samuels Y; Sherman E
    Cancer Res; 2021 Mar; 81(5):1279-1292. PubMed ID: 33355187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of activated c-Met with NRAS-mutated human melanomas.
    Chattopadhyay C; Ellerhorst JA; Ekmekcioglu S; Greene VR; Davies MA; Grimm EA
    Int J Cancer; 2012 Jul; 131(2):E56-65. PubMed ID: 22020736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.